Pushing Forward in Sarcoma with a New TCR Targeting NY-ESO-1
Overview
Overview
Journal
Cell Rep Med
Publisher
Cell Press
Specialties
Biology
General Medicine
General Medicine
Date
2023 Aug 16
PMID
37586326
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al. is a major step forward for adoptive T cell therapy in the clinical practice of advanced soft tissue sarcomas.
Citing Articles
Recent clinical researches and technological development in TIL therapy.
Matsueda S, Chen L, Li H, Yao H, Yu F Cancer Immunol Immunother. 2024; 73(11):232.
PMID: 39264449 PMC: 11393248. DOI: 10.1007/s00262-024-03793-4.
References
1.
Scanlan M, Gure A, Jungbluth A, Old L, Chen Y
. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002; 188:22-32.
DOI: 10.1034/j.1600-065x.2002.18803.x.
View
2.
Pollack S, Jungbluth A, Hoch B, Farrar E, Bleakley M, Schneider D
. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012; 118(18):4564-70.
PMC: 3361576.
DOI: 10.1002/cncr.27446.
View
3.
Jungbluth A, Antonescu C, Busam K, Iversen K, Kolb D, Coplan K
. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer. 2001; 94(2):252-6.
DOI: 10.1002/ijc.1451.
View
4.
DAngelo S, Melchiori L, Merchant M, Bernstein D, Glod J, Kaplan R
. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 T Cells in Synovial Sarcoma. Cancer Discov. 2018; 8(8):944-957.
PMC: 8092079.
DOI: 10.1158/2159-8290.CD-17-1417.
View
5.
Chen Y, Scanlan M, Sahin U, Tureci O, Gure A, Tsang S
. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997; 94(5):1914-8.
PMC: 20017.
DOI: 10.1073/pnas.94.5.1914.
View